title: Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization.
abstract: A major problem with current cancer vaccines is that the induction of CD8 immune responses is rarely associated with antitumor benefits, mainly owing to multiple immune suppressions in established tumor lesions. In this study, we investigated if and how activation of endogenous CD4 T cells could be achieved to influence the suppressive tumor milieu and antitumor effect. We engineered a lentivector (lv) to express a nominal fusion Ag composed of hepatitis B surface protein and IgG2a Fc fragment (HBS-Fc-lv) to increase the magnitude of CD8 response but, more importantly, to induce effective coactivation of CD4 T cells. We found that, remarkably, immunization with HBS-Fc-lv caused significant regression of established tumors. Immunologic analysis revealed that, compared with HBS-lv without Fc fragment, immunization with HBS-Fc-lv markedly increased the number of functional CD8 and CD4 T cells and the level of Th1/Tc1-like cytokines in the tumor while substantially decreasing the regulatory T cell ratio. The favorable immunologic changes in tumor lesions and the improvement of antitumor effects from HBS-Fc-lv immunization were dependent on the CD4 activation, which was Fc receptor mediated. Adoptive transfer of CD4 T cells from the HBS-Fc-lv-immunized mice could activate endogenous CD8 T cells in an IFN-γ-dependent manner. We conclude that endogenous CD4 T cells can be activated by lv expressing Fc-tagged Ag to provide another layer of help--that is, creating a Th1/Tc1-like proinflammatory milieu within the tumor lesion to boost the effector phase of immune responses in enhancing the antitumor effect.
authors.affiliation: Immunology/Immunotherapy Program, Cancer Center, Medical College of Georgia, Georgia Health Sciences University, Augusta, GA 30912, USA.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Hong
authors.forename: Yibing
authors.initials: Y
authors.lastname: Peng
authors.forename: Haiyan
authors.initials: H
authors.lastname: Xiao
authors.forename: Michael
authors.initials: M
authors.lastname: Mi
authors.forename: David
authors.initials: D
authors.lastname: Munn
authors.forename: Yukai
authors.initials: Y
authors.lastname: He
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism / Q000637:transplantation; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use*; D005822:Genetic Vectors / Q000276:immunology / Q000627:therapeutic use*; D057809:HEK293 Cells; D006514:Hepatitis B Surface Antigens / Q000235:genetics / Q000627:therapeutic use; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D007249:Inflammation / Q000276:immunology / Q000473:pathology / Q000628:therapy; D016086:Lentivirus / Q000235:genetics / Q000276:immunology; D008213:Lymphocyte Activation / Q000235:genetics / Q000276:immunology*; D008546:Melanoma, Experimental / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010446:Peptide Fragments / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000378:metabolism / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D006514:Hepatitis B Surface Antigens; D007141:Immunoglobulin Fc Fragments; D010446:Peptide Fragments